Cargando…

Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence

Parkinson’s disease (PD) is the second most chronic neurodegenerative disorder worldwide. Deficit of monoamines, particularly dopamine, causes an individually varying compilation of motor and non-motor features. Constraint of presynaptic uptake extends monoamine stay in the synaptic cleft. This revi...

Descripción completa

Detalles Bibliográficos
Autor principal:	Müller, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018398/ https://www.ncbi.nlm.nih.gov/pubmed/33824605 http://dx.doi.org/10.2147/JEP.S267032

Ejemplares similares

Monoamine Reuptake Inhibitors in Parkinson's Disease
por: Huot, Philippe, et al.
Publicado: (2015)

THERAPY WITH AMINEPTINE, A DOPAMINE REUPTAKE INHIBITOR, IN PATIENTS WITH MAJOR DEPRESSION
por: Channabasavanna, S.M., et al.
Publicado: (1997)

Implications for Combination Therapy of Selective Monoamine Reuptake Inhibitors on Dopamine Transporters
por: Ahn, Hyomin, et al.
Publicado: (2023)

Selective serotonin reuptake inhibitors and Alzheimer’s disease
por: Mdawar, Bernadette, et al.
Publicado: (2019)

Chiral Resolution of the Enantiomers of the Slow-Onset Dopamine Reuptake Inhibitor CTDP-32476 and Their Activities
por: Froimowitz, Mark, et al.
Publicado: (2023)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

A dopamine and noradrenaline reuptake inhibitor (bupropion) does not alter exercise performance of bank voles
por: Jaromin, Ewa, et al.
Publicado: (2016)

Monoamine depletion by reuptake inhibitors
por: Hinz, Marty, et al.
Publicado: (2011)

Differential Effects of Novel Dopamine Reuptake Inhibitors on Interference With Long-Term Social Memory in Mice
por: Camats-Perna, Judith, et al.
Publicado: (2019)

Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
por: Edinoff, Amber N., et al.
Publicado: (2021)

A Physical Interaction between the Dopamine Transporter and DJ-1 Facilitates Increased Dopamine Reuptake
por: Luk, Beryl, et al.
Publicado: (2015)

Triple Reuptake Inhibitors: A Premise and Promise
por: Marks, David M., et al.
Publicado: (2008)

LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
por: Li, Nannan, et al.
Publicado: (2019)

The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials
por: Azizi, Marzieh, et al.
Publicado: (2022)

Selective serotonin reuptake inhibitors and cardiovascular events: A systematic review
por: Nezafati, Mohammad Hassan, et al.
Publicado: (2016)

Dopamine Receptors and Parkinson's Disease
por: Hisahara, Shin, et al.
Publicado: (2011)

A study to understand the pattern of hyponatremia in patients using selective serotonin reuptake inhibitors and serotonin dopamine antagonists
por: Tomar, Love Kumar, et al.
Publicado: (2021)

The Effects of LPM570065, a Novel Triple Reuptake Inhibitor, on Extracellular Serotonin, Dopamine and Norepinephrine Levels in Rats
por: Zhang, Renyu, et al.
Publicado: (2014)

What Mechanisms Are Responsible for the Reuptake of Levodopa-Derived Dopamine in Parkinsonian Striatum?
por: Nishijima, Haruo, et al.
Publicado: (2016)

Heterogeneities in Axonal Structure and Transporter Distribution Lower Dopamine Reuptake Efficiency
por: Kaya, Cihan, et al.
Publicado: (2018)

Role of dopamine in the pathophysiology of Parkinson’s disease
por: Zhou, Zhi Dong, et al.
Publicado: (2023)

Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence
por: Siepmann, Timo, et al.
Publicado: (2015)

Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis
por: Wozniak, Greta, et al.
Publicado: (2011)

Confounding by Indication in Studies of Selective Serotonin Reuptake Inhibitors
por: Lee, Jimin, et al.
Publicado: (2022)

Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease
por: Ye, Zheng, et al.
Publicado: (2014)

New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations
por: Fanelli, David, et al.
Publicado: (2021)

Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction
por: Nguyen, Thanh Thanh L., et al.
Publicado: (2021)

Candidate genes for antidepressant response to selective serotonin reuptake inhibitors
por: Lotrich, Francis E, et al.
Publicado: (2005)

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
por: Briley, Mike, et al.
Publicado: (2010)

Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging
por: Heng, Nicholas, et al.
Publicado: (2023)

Temporal Expression of Mutant LRRK2 in Adult Rats Impairs Dopamine Reuptake
por: Zhou, Hongxia, et al.
Publicado: (2011)

Fatigue-related impairments in oculomotor control are prevented by norepinephrine-dopamine reuptake inhibition
por: Connell, Charlotte J. W., et al.
Publicado: (2017)

Impaired dopamine release in Parkinson’s disease
por: Cramb, Kaitlyn M L, et al.
Publicado: (2023)

A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
por: Zhong, Zhuoyuan, et al.
Publicado: (2017)

Monoamine Depletion by Reuptake Inhibitors [Retraction]
Publicado: (2020)

Pharmacological and Behavioral Characterization of D-473, an Orally Active Triple Reuptake Inhibitor Targeting Dopamine, Serotonin and Norepinephrine Transporters
por: Dutta, Aloke K., et al.
Publicado: (2014)

Structural Requirements for Modulating 4-Benzylpiperidine Carboxamides from Serotonin/Norepinephrine Reuptake Inhibitors to Triple Reuptake Inhibitors
por: Paudel, Suresh, et al.
Publicado: (2021)

Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms
por: Wadhwa, Ravisha, et al.
Publicado: (2017)

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
por: Haddad, Fatma, et al.
Publicado: (2017)

Impaired dopamine metabolism in Parkinson’s disease pathogenesis
por: Masato, Anna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vkie9clrhovk8rpm9j8rsteo68